SAN DIEGO and PHOENIX, Oct. 7, 2024 /PRNewswire/ — Presentations by Aspen Neuroscience Chief Scientific Officer Xiaokui Zhang, Ph.D. and Chief Technology Officer Kim Raineri will highlight the latest therapeutic and corporate developments, at the annual Cell & Gene Meeting on the Mesa, held this week in Phoenix, Ariz. and live-streamed globally.

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference featuring more than 120 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers.

Today, Aspen’s CSO Dr. Zhang will present as a member of a panel of industry experts. The 4 p.m. panel, “Science Slam: Neurological Diseases,” will focus on biomarkers and endpoints development for neurodegenerative indications in the cell and gene therapy space, and provide an overview of recent progress in the field.

On Tuesday CTO Kim Raineri will present a corporate overview, highlighting Aspen’s work in the development of iPSC-derived cell therapies for the treatment of CNS disorders, beginning with Parkinson’s Disease (PD). The company recently announced it has completed dosing of the first cohort of patients in the ASPIRO Phase 1/2a clinical trial of ANPD001, a personalized (autologous) cell therapy to treat Parkinson’s Disease by replacing lost dopamine neurons.

The following are specific details regarding Aspen Neuroscience’s presentations at the conference:

Presenter:	Xiaokui Zhang, Ph.D.
Event:	Science Slam: Neurological Diseases
Date:	Monday, October 07, 2024
Time:	4 p.m.
Location:	Arizona Biltmore, FLW Ballroom F
Presenter:	Kim Raineri
Event:	Aspen Neuroscience Company Presentation
Date:	Tuesday, October 08, 2024
Time:	1:30 p.m.
Location:	Arizona Biltmore, FLW Ballroom G

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Virtual attendance is available, which includes a livestream of both Aspen Neuroscience presentations and the ability to view all conference sessions on-demand. Please visit https://meetingonthemesa.com for full information including registration.

About Aspen Neuroscience
Headquartered in San Diego, Aspen Neuroscience, Inc. is a clinical development-stage, private company focused on autologous regenerative medicine. The company’s patient-derived platform is used to create personalized cell therapies to address diseases with high unmet medical needs, beginning with autologous neuron replacement for PD. For more information and important updates, please visit https://www.aspenneuroscience.com.

SOURCE Aspen Neuroscience, Inc.

SAN DIEGO and PHILADELPHIA , Sept. 26, 2024 /PRNewswire/ — Aspen Neuroscience announced today that it has successfully completed dosing of the first cohort of patients in the ASPIRO study. Surgical safety data from this cohort has been accepted for late breaking presentations this week at the MDS International Congress of Parkinson’s Disease and Movement Disorders, taking place in Philadelphia September 27 – October 1.

“We are honored to have been accepted by the Society to present surgical safety from our first cohort of patients in our first-in-human trial,” said Edward Wirth III, MD, PhD, Chief Medical Officer of Aspen Neuroscience.  “We have made tremendous progress since launching the study earlier this year, and we look forward to sharing these data with our esteemed movement disorder colleagues.”

The Autologous-derived Study of a Parkinson’s Investigational Regenerative therapy in an Open-label trial (ASPIRO) is a Phase 1/2a clinical trial to assess the safety, tolerability, and potential efficacy of ANPD001 in patients with moderate to severe Parkinson’s disease (PD). The primary study endpoint is safety and tolerability of ANPD001.

The cell transplantation approach used in the study was developed by the trial’s lead neurosurgeon and renowned MRI-guided stereotactic neurosurgery pioneer Paul Larson, MD, FAANS, professor of neurosurgery at the University of Arizona College of Medicine – Tucson and neurosurgeon at Banner University Medical Center, Tucson.

In addition to multiple scientific presentations, Aspen will participate as a Bronze Level sponsor, showcasing company highlights at booth #1003.

The Aspen Neuroscience schedule of presentations includes:

Presenter:	Paul Larson, MD, FAANS Lead surgeon, ASPIRO study Professor of neurosurgery at the University of Arizona College of Medicine – Tucson and neurosurgeon at Banner University Medical Center, Tucson
Event	Oral Platform Presentation 9: Late-Breaking Abstracts
Title:	First in Human Administration of an Autologous Investigational Cell Therapy for Parkinson Disease Using an Intraoperative MRI-guided Posterior Approach
Date:	Sunday, September 29
Time:	1:30-2:30pm ET
Location:	Meeting Room 107 AB, Ground Level
Presenters:	Paul Larson, MD, FAANS Lead surgeon, ASPIRO study Edward Wirth III, MD, PhD Chief Medical Officer, Aspen Neuroscience
Event:	Poster Presentations
Title:	First in Human Administration of an Autologous Investigational Cell Therapy for Parkinson Disease Using an Intraoperative MRI-guided Posterior Approach
Abstract #	LBA-9
Category:	Parkinson’s Disease: Clinical Trials
Dates:	September 28 – 30
Time:	1-3pm ET
Location:	Exhibit Hall A

About Aspen Neuroscience
Aspen Neuroscience, Inc., headquartered in San Diego, is dedicated to autologous regenerative medicine. The company’s patient-derived iPSC platform is used to create personalized therapies, a crucial step in addressing diseases with high unmet medical needs, starting with autologous neuron replacement for Parkinson’s disease.

Aspen combines cell biology with the latest machine learning and genomic approaches to investigate patient-specific, restorative cell treatments. The company’s unwavering commitment to quality is evident in its best-in-class platform to create and optimize pluripotent-derived cell therapies, which includes in-house bioinformatics, manufacturing, and quality control.  For more information, visit www.aspenneuroscience.com 

SOURCE Aspen Neuroscience, Inc.

SAN DIEGO, June 14, 2023 /PRNewswire/ — Today Aspen Neuroscience, Inc. co-founder and Senior Vice President, Research & Development, Andrés Bratt-Leal, PhD, will present “Enabling Autologous iPSC-Derived Cell Therapies with Predictive Genomics,” during the Focus Sessions taking place during this week’s 2023 International Society for Stem Cell Research (ISSCR) Annual Meeting in Boston, Mass.

His presentation will cover experiences with induced pluripotent stem cell (iPSC) program advancement and progression into GMP-Compliant manufacturing for pre-clinical and clinical development.

Dr. Bratt-Leal will also join the panel discussion, “Functional Investigation and Clinical Development of iPSC-Based Therapies,” featuring first-hand experience from leading experts in the field. The panel discussion will cover a broad range of topics including selecting methodological approaches for iPSC generation and differentiation, GMP-compliant manufacturing, pre-clinical and clinical study design, and clinical-trial management.

Aspen Neuro is working to develop an autologous cell therapy designed to replace lost dopamine neurons for people with Parkinson’s Disease (PD). Currently there is no disease-modifying treatment for PD, the second most common neurodegenerative disease affecting more than 10 million patients worldwide. One of the advantages of the autologous approach is that it will not require immunosuppressive drugs.

The ISSCR annual meeting gathers the world’s leading scientists, clinicians, business leaders, ethicists and educators from more than 65 countries to commemorate 20 years of excellence, advances, and contributions of stem cell research and regenerative medicine.

The “Functional Investigation and Clinical Development of iPSC-Based Therapies” Focus Session is sponsored by Allele Biotechnology.

About Aspen Neuroscience
Headquartered in San Diego, Aspen Neuroscience, Inc. is a development stage, private biotechnology company focused on personalized (autologous) cell therapies. The company is developing iPSC-derived therapies to address diseases with high unmet medical need, beginning with autologous neuron replacement for Parkinson’s disease (PD) and extending across the brain and affected organs.

A leading iPSC platform company, Aspen combines stem cell biology with the latest artificial intelligence and genomic approaches to investigate patient-specific, restorative treatments. The company has developed a best-in-class platform to create and characterize pluripotent-derived cell medicines, which includes in-house bioinformatics, manufacturing and QC. For more information and important updates, please visit aspenneuroscience.com.

SOURCE Aspen Neuroscience, Inc.